These press releases are intended for business journalists and analysts/investors
GSK Australia today welcomed the addition of Meningococcal B (MenB) vaccination for Aboriginal and Torres Strait Islander infants to the National Immunisation Program (NIP)1 as well as people of all ages with some medical conditions that increase their risk of Invasive Meningococcal Disease (IMD).
Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of NUCALA® (mepolizumab)
GSK Australia today announced that a new pre-filled pen (autoinjector) for the self-administration of its targeted therapy for severe eosinophilic asthma patients, NUCALA (mepolizumab), will be reimbursed by the Pharmaceutical Benefits Scheme (PBS) from 1 June 2020.
GlaxoSmithKline (GSK) Australia has reported its 2019 results to the Australian Securities and Investment Commission (ASIC) for its pharmaceuticals and vaccines business, and ViiV Healthcare Australia (a joint venture with Pfizer and Shionogi focused on HIV). GSK Australia’s Consumer Healthcare business will report separately in the coming months.
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine
Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021
GSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer, following an agreement reached with Takeda Australia. This transfer of marketing authorisation is an important first step in the process for GSK to make this medicine available to Australian patients.
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
GSK to make adjuvant technology available to support rapid development of candidate vaccines
We are all deeply saddened at the devastation caused by the Australian bushfires and the impact on people and wildlife in affected communities, particularly in the states of Queensland, New South Wales, Victoria and South Australia.
Professor Brendan Crabb wins 2019 GSK Award for Research Excellence
“There is probably no more impactful contribution to human development than ridding the world of malaria,” says winner
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.